FFA Sciences

FFA Sciences has developed a proprietary, patented platform based on fluorescently labeled fatty acid-binding proteins (FABPs), such as ADIFAB and ADIFAB2, to measure unbound free fatty acids in biological fluids in under a minute. While its initial focus is on ophthalmology, where FFAu is implicated in diseases like diabetic retinopathy and dry AMD, the technology has broad applicability in drug discovery, enzymology, and metabolomics profiling. The company generates revenue through the sale of assay kits and reagents, as well as providing contract research services, positioning it as a tools and services company rather than a therapeutic developer.

Patented fluorescent assay platform using engineered fatty acid-binding proteins (FABPs) to measure unbound free fatty acids (FFAu) in biological samples in real-time. The platform includes broad-spectrum probes (ADIFAB/ADIFAB2) and is being expanded to include probes with enhanced specificity for individual fatty acids and metabolites for metabolomics profiling.

FFA Sciences holds a unique position with its patented method for direct FFAu measurement, facing little direct competition for this specific parameter. However, it competes indirectly with broader reagent suppliers and analytical service providers. In metabolomics, it will face competition from established mass spectrometry-based profiling services and reagent vendors. Its success depends on convincing researchers that its specific, real-time fluorescent assay provides advantages over more generic or total concentration methods.